Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Donating Tissues for Research

Miscellaneous

Miscellaneous
N/A
Washington, Mary Kay
VICCBIO0478

REACH (Research, Education, Advocacy, Clinical Care and Health) for Survivorship Program: Long Term Effects for Survivors of Cancer

Multiple Cancer Types

Miscellaneous, Pediatrics
N/A
Esbenshade, Adam
VICCPED0710

Severe Chronic Neutropenia International Registry

Benign Hematologic

Benign Hematologic
N/A
McDaniel, Heather
VICCNCPED10104

Hematologic Malignancy Tumor Bank

Multiple Cancer Types

Hematologic, Leukemia, Lymphoma
N/A
Seegmiller, Adam
VICCHEM1217

Lung Cancer Screening Program at VICC: Correlative Study

Lung

Lung
N/A
Sandler, Kim
VICCTHO1496

Infectious Disease Outcomes in Pediatric Oncology Patients

Multiple Cancer Types

Miscellaneous, Pediatrics
N/A
Esbenshade, Adam
VICCPED14127

Bone Marrow Bank

Not Available
N/A
Thompson Arildsen, Mary Ann
VICCPED1522

Mount Sinai Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository

Miscellaneous

Miscellaneous
N/A
Kitko, Carrie
VICCPED1544

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People with Advanced Alveolar Soft Part Sarcoma

Sarcoma

This phase II trial studies how well atezolizumab or atezolizumab plus bevacizumab works in treating patients with alveolar soft part sarcoma that has not been treated, has spread from where it started to other places in the body (advanced) and cannot be removed by surgery (unresectable). Atezolizumab works by unblocking the immune system, allowing the immune system cells to recognize and then attack tumor cells. Bevacizumab works by controlling the growth of new blood vessels. Giving atezolizumab alone or atezolizumab with bevacizumab may shrink the cancer.
Sarcoma
II
Davis, Elizabeth
NCT03141684
VICCSAR16155ET-CT

Accelerated or Standard BEP Chemotherapy in Treating Patients with Intermediate or Poor-Risk Metastatic Germ Cell Tumors

Germ Cell (Pediatrics)

This phase III trial compares the effect of an accelerated schedule of bleomycin sulfate, etoposide phosphate, and cisplatin (BEP) chemotherapy to the standard schedule of BEP chemotherapy for the treatment of patients with intermediate or poor-risk germ cell tumors that have spread to other places in the body (metastatic). Drugs used in chemotherapy, such as bleomycin sulfate, etoposide phosphate, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BEP chemotherapy on a faster, or accelerated schedule may work better with fewer side effects in treating patients with intermediate or poor-risk metastatic germ cell tumors compared to the standard schedule.
Germ Cell (Pediatrics)
III
Borinstein, Scott
NCT02582697
COGAGCT1532

To learn more about any of our clinical
trials, call 615-936-8422.